MPAR

Global Antibiotic Resistance Market to Hit US$16.5 Billion By 2030

Retrieved on: 
Thursday, April 21, 2022
CSE, AMR, Project, Opioid, U.S. Securities and Exchange Commission, COVID-19, Security (finance), NASDAQ, Research, Article, Diagnosis, Infection, Hospital, CAGR, Patient, CpG, ICU, Securities Exchange Act of 1934, Review, Technology, UBC, Drug, Forward-looking statement, 1018, ANY, Securities Act of 1933, Annual report, DCGI, CSA, Private Securities Litigation Reform Act, Biological E. Limited, RNA, Conference, Mortality, Solution, Sepsis, Disease, Septic shock, News, ASEP, COO, Growth, MPAR, Commercial, Industry, Prevalence, Cancer, Immunity, FNM, Drugs Controller General of India, Death, Form 10-K, Vaccine, Biology, CAR, NOT, Organ dysfunction, Length of stay, Physician, MSC, Pharmaceutical industry, Financial adviser, ImmunityBio, Nafamostat, Amyris, Author

NEW YORK, April 21, 2022 /PRNewswire/ -- Resistance to antibiotics is a growing concern. About 750,000 people die each year worldwide from drug–resistance infections. If solutions aren't found and put in place, 10 million people could die from antibiotic resistance-related diseases by 2050. According to SPER Market Research, the global antimicrobial resistance (AMR) market was valued at US$10.2 billion in 2021 and estimated at US$16.4 billion by 2030 with a CAGR of 5.74%. The main cause of death from COVID-19 is sepsis, a serious medical condition caused by the body's reaction to an infection. ASEP Medical Holdings Inc. (CSE:ASEP) (OTCQB:SEPSF) proposes to address this problem with a new diagnostic capable of detecting the dysfunctional immune response underlying the most severe form of sepsis. Other companies like ImmunityBio, Inc. (NASDAQ:IBRX), Dynavax Technologies Corporation (NASDAQ:DVAX), Allogene Therapeutics (NASDAQ:ALLO) and Ensysce Biosciences (NASDAQ:ENSC) are looking to combat COVID-19 and cancer.

Key Points: 
  • If solutions aren't found and put in place, 10 million people could die from antibiotic resistance-related diseases by 2050.
  • According to SPER Market Research, the global antimicrobial resistance (AMR) market was valued at US$10.2 billion in 2021 and estimated at US$16.4 billion by 2030 with a CAGR of 5.74%.
  • The company, which entered the public markets in December 2021, just commenced trading on the OTCQB Venture market under the symbol SEPSF.
  • Sepsis, which occurred in 48.9 million people worldwide and caused 11 million deaths globally in 2017, has become increasingly concerning during the global pandemic.

Global Antibiotic Resistance Market to Hit US$16.5 Billion By 2030

Retrieved on: 
Thursday, April 21, 2022
CSE, AMR, Project, Opioid, U.S. Securities and Exchange Commission, COVID-19, Security (finance), NASDAQ, Research, Article, Diagnosis, Infection, Hospital, CAGR, Patient, CpG, ICU, Securities Exchange Act of 1934, Review, Technology, UBC, Drug, Forward-looking statement, 1018, ANY, Securities Act of 1933, Annual report, DCGI, CSA, Private Securities Litigation Reform Act, Biological E. Limited, RNA, Conference, Mortality, Solution, Sepsis, Disease, Septic shock, News, ASEP, COO, Growth, MPAR, Commercial, Industry, Prevalence, Cancer, Immunity, FNM, Drugs Controller General of India, Death, Form 10-K, Vaccine, Biology, CAR, NOT, Organ dysfunction, Length of stay, Physician, MSC, Pharmaceutical industry, Financial adviser, ImmunityBio, Nafamostat, Amyris, Author

NEW YORK, April 21, 2022 /PRNewswire/ -- Resistance to antibiotics is a growing concern. About 750,000 people die each year worldwide from drug–resistance infections. If solutions aren't found and put in place, 10 million people could die from antibiotic resistance-related diseases by 2050. According to SPER Market Research, the global antimicrobial resistance (AMR) market was valued at US$10.2 billion in 2021 and estimated at US$16.4 billion by 2030 with a CAGR of 5.74%. The main cause of death from COVID-19 is sepsis, a serious medical condition caused by the body's reaction to an infection. ASEP Medical Holdings Inc. (CSE:ASEP) (OTCQB:SEPSF) proposes to address this problem with a new diagnostic capable of detecting the dysfunctional immune response underlying the most severe form of sepsis. Other companies like ImmunityBio, Inc. (NASDAQ:IBRX), Dynavax Technologies Corporation (NASDAQ:DVAX), Allogene Therapeutics (NASDAQ:ALLO) and Ensysce Biosciences (NASDAQ:ENSC) are looking to combat COVID-19 and cancer.

Key Points: 
  • If solutions aren't found and put in place, 10 million people could die from antibiotic resistance-related diseases by 2050.
  • According to SPER Market Research, the global antimicrobial resistance (AMR) market was valued at US$10.2 billion in 2021 and estimated at US$16.4 billion by 2030 with a CAGR of 5.74%.
  • The company, which entered the public markets in December 2021, just commenced trading on the OTCQB Venture market under the symbol SEPSF.
  • Sepsis, which occurred in 48.9 million people worldwide and caused 11 million deaths globally in 2017, has become increasingly concerning during the global pandemic.

Ensysce Biosciences Reports Second Quarter 2021 Financial Results and Recent Corporate Updates

Retrieved on: 
Monday, August 16, 2021
NIDA, Company, Opioid use disorder, Drug discovery, Death, Pain, Form, Communication, GLOBE, Drug, OUD, Sexual abuse, Research, Grant, Food, Patent, CA, Time, Forward-looking statement, National Institute on Drug Abuse, ADHD, Expense, Clinical trial, NASDAQ, IND, OTC, Composition, SAN, CEO, MPAR, Â, Opioid, COVID-19, National Institute, United States Patent and Trademark Office, General officer, Regulation of tobacco by the U.S. Food and Drug Administration, Pharmaceutical industry, Cereal, Generic drug

SAN DIEGO, Aug. 16, 2021 (GLOBE NEWSWIRE) -- Ensysce Biosciences, Inc. (Ensysce or the Company) (NASDAQ: ENSC, OTC: ENSCW), a clinical-stage biotech company with proprietary technology platforms to reduce the economic and social burden of prescription drug abuse and overdose, today reported financial results for the second quarter of 2021 and recent corporate updates.

Key Points: 
  • SAN DIEGO, Aug. 16, 2021 (GLOBE NEWSWIRE) -- Ensysce Biosciences, Inc. (Ensysce or the Company) (NASDAQ: ENSC, OTC: ENSCW), a clinical-stage biotech company with proprietary technology platforms to reduce the economic and social burden of prescription drug abuse and overdose, today reported financial results for the second quarter of 2021 and recent corporate updates.
  • Federal Grants - Funding under federal grants was $0.4 million for the second quarter of 2021 compared to $1.8 million for the second quarter of 2020.
  • G&A Expenses - General and administrative expenses were $0.4 million for the second quarter of 2021 compared to $0.3 million for the second quarter of 2020.
  • Net Loss - Net loss for the second quarter of 2021 was $1.0 million compared to $0.7 million for the same period in 2020.